|
rs7717457
|
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Conclusions</b>: SNP rs7717457 is associated with the selection of HBV BCP double mutations, providing an important clue to understanding the mechanisms of oncogenesis of HBV BCP double mutations.
|
31341412 |
2019 |
|
rs771939956
|
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>De novo</i> tumorigenesis was not significantly increased in either heterozygous (<i>p53<sup>334R/H</sup></i> ) or homozygous (<i>p53<sup>334H/H</sup></i> ) p53 R334H knockin mice compared with wild-type mice.
|
30042151 |
2018 |
|
rs573154688
|
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>De novo</i> tumorigenesis was not significantly increased in either heterozygous (<i>p53<sup>334R/H</sup></i> ) or homozygous (<i>p53<sup>334H/H</sup></i> ) p53 R334H knockin mice compared with wild-type mice.
|
30042151 |
2018 |
|
rs664589
|
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>In vitro</i> and <i>in vivo</i> experiments showed that the rs664589 C to G mutation facilitated carcinogenesis and metastasis of colorectal cancer.
|
31311811 |
2019 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumorigenesis was measured in the Kras(G12D/+);Ptf1a(Cre/+) mouse model of PDA; these mice were crossed with mice with pancreas-specific disruption of genes encoding PI3K p110α (Pik3ca), p110β (Pik3cb), or RAC1 (Rac1).
|
25311989 |
2014 |
|
rs752021744
|
|
Carcinogenesis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Tumorigenesis was measured in the Kras(G12D/+);Ptf1a(Cre/+) mouse model of PDA; these mice were crossed with mice with pancreas-specific disruption of genes encoding PI3K p110α (Pik3ca), p110β (Pik3cb), or RAC1 (Rac1).
|
25311989 |
2014 |
|
rs4680
|
|
Carcinogenesis
|
|
0.040 |
GeneticVariation
|
BEFREE |
Val158Met is a common single-nucleotide polymorphism of the COMT gene (Ex4-12 G>A; rs4680) that results in a lower activity enzyme, increasing susceptibility to tumorigenesis.
|
17636223 |
2007 |
|
rs2303426
|
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
A case-control study (230 GB carcinogenesis patients and 230 controls) was undertaken to evaluate whether genetic variations in 3 DNA repair genes ERCC2 (Asp312Asn [rs1799793] and Lys751Gln [rs13181]), MSH2 (-118T > C [rs2303425] and IVS1 + 9G>C [rs2303426]), and OGG1 (Ser326Cys [rs1052133] and 748-15C > G [rs2072668]) are associated with GB carcinogenesis risk in a North Indian population.
|
20564624 |
2010 |
|
rs1052133
|
|
Carcinogenesis
|
|
0.040 |
GeneticVariation
|
BEFREE |
A case-control study (230 GB carcinogenesis patients and 230 controls) was undertaken to evaluate whether genetic variations in 3 DNA repair genes ERCC2 (Asp312Asn [rs1799793] and Lys751Gln [rs13181]), MSH2 (-118T > C [rs2303425] and IVS1 + 9G>C [rs2303426]), and OGG1 (Ser326Cys [rs1052133] and 748-15C > G [rs2072668]) are associated with GB carcinogenesis risk in a North Indian population.
|
20564624 |
2010 |
|
rs2072668
|
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
A case-control study (230 GB carcinogenesis patients and 230 controls) was undertaken to evaluate whether genetic variations in 3 DNA repair genes ERCC2 (Asp312Asn [rs1799793] and Lys751Gln [rs13181]), MSH2 (-118T > C [rs2303425] and IVS1 + 9G>C [rs2303426]), and OGG1 (Ser326Cys [rs1052133] and 748-15C > G [rs2072668]) are associated with GB carcinogenesis risk in a North Indian population.
|
20564624 |
2010 |
|
rs11655237
|
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
A G>A change at rs11655237 in exon 4 of LINC00673 creates a target site for miR-1231 binding, which diminishes the effect of LINC00673 in an allele-specific manner and thus confers susceptibility to tumorigenesis.
|
27213290 |
2016 |
|
rs4680
|
|
Carcinogenesis
|
|
0.040 |
GeneticVariation
|
BEFREE |
A genetic variant Val158Met in the COMT gene leads to a several-fold decrease in the enzymatic activity giving rise to the accumulation of potentially carcinogenic endogenous catechol estrogens and their reactive intermediates and increasing thus the risk of tumorigenesis.
|
27826992 |
2017 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
A large number of studies in the past decade have tried to dissect the relevance and the function of the V600E mutation in controlling oncogenesis and progression of thyroid cancer.
|
24828987 |
2015 |
|
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
A large number of studies in the past decade have tried to dissect the relevance and the function of the V600E mutation in controlling oncogenesis and progression of thyroid cancer.
|
24828987 |
2015 |
|
rs121913521
|
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
A number of chromosomal loci are likely to be involved in the PDGFRA V561D-dependent tumorigenesis, as shown by CGH and other DNA analyses.
|
17566086 |
2007 |
|
rs121908586
|
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
A number of chromosomal loci are likely to be involved in the PDGFRA V561D-dependent tumorigenesis, as shown by CGH and other DNA analyses.
|
17566086 |
2007 |
|
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600E), as a result of the BRAF(T1799A) mutation, plays a fundamental role in thyroid tumorigenesis.
|
21185263 |
2011 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600E), as a result of the BRAF(T1799A) mutation, plays a fundamental role in thyroid tumorigenesis.
|
21185263 |
2011 |
|
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600E), as a result of the BRAF(T1799A) mutation, plays a fundamental role in thyroid tumorigenesis.
|
21185263 |
2011 |
|
rs776935407
|
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600E), as a result of the BRAF(T1799A) mutation, plays a fundamental role in thyroid tumorigenesis.
|
21185263 |
2011 |
|
rs17227424
|
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Absence of the wild-type allele in tumors carrying the E530D variant suggests a possible role for this change in tumorigenesis.
|
14605947 |
2003 |
|
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
According to the literature, our data provide evidence of the BRAF and RAS roles in thyroid tumorigenesis, supporting an association between BRAF (V600E) mutations and the more aggressive clinical and pathological features of thyroid tumors.
|
29435002 |
2018 |
|
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
According to the literature, our data provide evidence of the BRAF and RAS roles in thyroid tumorigenesis, supporting an association between BRAF (V600E) mutations and the more aggressive clinical and pathological features of thyroid tumors.
|
29435002 |
2018 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Administration of a CXCL16-neutralizing antibody to KRAS(G12D) mice reduced activation of PI3K signaling to AKT and NF-κB, blocking carcinogenesis.
|
25683115 |
2015 |
|
rs727503094
|
|
Carcinogenesis
|
|
0.040 |
GeneticVariation
|
BEFREE |
Administration of a CXCL16-neutralizing antibody to KRAS(G12D) mice reduced activation of PI3K signaling to AKT and NF-κB, blocking carcinogenesis.
|
25683115 |
2015 |